Optalert developed the world's leading algorithm to quantify the deterioration in cognitive brain function due to drowsiness and created the Johns Drowsiness Scale (JDS) which remains the only scientifically proven, objective measurement of drowsiness.The JDS is used worldwide in research for accurately quantifying drowsiness levels, and in Optalert's early-warning drowsiness detection systems to protect thousands of lives and valuable company assets across multiple industries. Our clients include BHP Billiton, Vale and NASA. Our research partners include the Harvard Medical School, Monash University, and the University of Queensland.Optalert is a Medical Technology company pioneering the use of Blepharometry (the measurement of blinks) to measure drowsiness. Optalert discovered a key biomarker for drowsiness, the connection between brain function and eyelid movement.Optalert is now turning its extensive expertise in Blepharometry and Artificial Intelligence to identify the biomarkers for other degradations to neurological brain function in conditions such as Epilepsy (due to onset of seizures), ADHD, Parkinson's, Alzheimer's, TBI, concussion and motor neuron disease.

Fatigue Management Alertness Monitoring Fatigue Risk Profiling Drowsiness Detection Wearable Technology Early warning drowsiness detection Data reporting Risk reduction from Fatigue related accidents Licensing Pharmaceutical Epworth Sleepiness Scale Johns Drowsiness Scale JDS ESS Medical Trials Clinical Trials machine learning neurology Sleep BIOtech Epilepsy Shiftwork TBI Traumatic Brain Injury Wakefulness Automotive Inattention OEM Distraction

Optalert Limited is a pioneering medical technology company that has developed a revolutionary algorithm to quantify the deterioration in cognitive brain function due to drowsiness. With its headquarters located in Burnley, Victoria, Australia, the company has made a significant impact in the BioTech/Drugs industry. Optalert's mission is to protect thousands of lives and valuable company assets across multiple industries by accurately measuring drowsiness levels through its early-warning drowsiness detection systems. The company's flagship product, the Johns Drowsiness Scale (JDS), is the only scientifically proven, objective measurement of drowsiness. The JDS has been widely adopted in research and industry, and has been used by prominent clients such as BHP Billiton, Vale, and NASA. Optalert's technology has also been recognized by leading research institutions, including Harvard Medical School, Monash University, and the University of Queensland, with whom the company has collaborated on various projects. Optalert's innovative approach to drowsiness detection is based on the measurement of blinks, known as Blepharometry. By analyzing the connection between brain function and eyelid movement, the company has discovered a key biomarker for drowsiness. This technology has far-reaching implications, as it can be used to identify biomarkers for other neurological brain function degradations, such as Epilepsy, ADHD, Parkinson's, Alzheimer's, TBI, concussion, and motor neuron disease. Led by a team of experienced executives, including Simon Block, Scott Coles, and Nicolas Gerbal, Optalert is poised to continue its groundbreaking work in the field of drowsiness detection and neurological brain function. With its cutting-edge technology and commitment to innovation, the company is set to make a significant impact in the medical technology industry for years to come.

Optalert created a way to measure how tired people are by looking at how often they blink. This is called the Johns Drowsiness Scale (JDS). It's the only proven way to measure drowsiness, and it's used all over the world in research and in systems that help prevent accidents caused by tiredness. Optalert works with big companies like BHP Billiton, Vale, and NASA, and with universities like Harvard Medical School, Monash University, and the University of Queensland. Now, Optalert is using its expertise to find ways to measure other problems with the brain, like Epilepsy, ADHD, Parkinson's, Alzheimer's, TBI, concussion, and motor neuron disease.